A Systematic Overview of Chemotherapy Effects in Acute Myeloid Leukaemia

References

• Bloomfield CD, Shuma C, Regal L, et al. Long-term survival of patients with acute myeloid leukemia: a third follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer 1997; 80 (Suppl): 2191–8. (L)
   Google Scholar
• Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine in-tensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998; 58: 4173-9. (R2/285)
   Google Scholar
• Grimwade D, Walker H, Wheatley K, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1(612 patients enterred into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322-33. (R1/1612)
   Google Scholar
• Ellison RR, Holland JF, Weil M, et al. Arabinosyl cytosine: A useful agent in the treatment of acute leukaemia. Blood 1968; 32: 507-23. (C2/234)
   Google Scholar
• Plunkett W, Iacoboni S, Keating MJ, et al. Cellular pharma-cology and optimal theurapeutic concentrations of 1-beta-D-arabinofuranosylcytosine triphosphate in leukemic blasts during treatment of refractory leukaemia with high dose 1-beta-D-arabino furanosylcytosine. Scand J Haematol 1986; 44: 51-9. (0)
   Google Scholar
• Dillman RO, Davis RB, Green M, et al. Comparison of ara-C at 200 mg/m2 and 100 mg/m2 in induction and maintenance therapy for acute myelocytic leukaemia. Proc Am Soc Clin Oncol 1987; 6: Abstr 160. (C3/98)
   Google Scholar
• Dillman RO, Davis RB, Green M, et al. A comparative study of two different doses of cytarabin for acute myeloid leukaemia: A phase III trial of Cancer and Leukaemia Group B. Blood 1991; 78: 2520-6. (C1/326)
   Google Scholar
• Bishop JF, Matthews JP, Young GA, et al. A randomised study of high-dose cytarabine in induction in acute myeloid leukaemia. Blood 1996; 87: 1710-7. (C1/301)
   Google Scholar
• Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomised investigation of high-dose vs standard dose cytosine ara-binoside with daunorubicin in patients with previously un-treated acute myeloid leukaemia, a South West Oncology Group study. Blood 1996; 88: 2841-51. (C1/665)
   Google Scholar
• Boiron M, Jaquillat C, Weil M, et al. Daunorubicin in the treatment of acute myelocytic leukaemia. Lancet 1969; 1: 330–3. (P2/64, 48 adults)
   PubMed Web of Science ®Google Scholar
• Weil M, Glidewell OJ, Jaquillat C, et al. Daunorubicin in the therapy of acute granulocytic leukaemia. Cancer Res 1973; 33: 921-8. (0)
   Google Scholar
• Bfichner T, Urbanitz D, Emmerich B, et al. Multicenter study on intensified remission induction therapy for acute myeloid leukaemia. Leukaemia Res 1982; 6: 827-31. (P1/213)
   Google Scholar
• Mayer RJ. Current chemotherapeutic treatment approaches to the management of untreated adults with de novo acute myelogenous leukaemia. Semin Oncol 1987; 14: 384–96. (L)
   PubMed Web of Science ®Google Scholar
• Hewlett J, Kopecky KJ, Head D, et al. A prospective evaluation of the value of bone marrow transplantation and low dose maintenance chemotherapy in the treatment for adult acute myelogenous leukaemia (AML). Leukaemia 1995; 9: 562–9. (P2/522, 295 in CR of whom 150 were randomised, C3/150)
   PubMed Web of Science ®Google Scholar
• Yates J, Glidwell O, Wiernik P, et al. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelo-cytoid leukaemia. A CALGB study. Blood 1982; 60: 454-62. (C2/226)
   Google Scholar
• Berman E, Raymond W, Daghestani A, et al. 4-Demethoxy daunorubicin (idarubicin) in combination with 1-beta D-ara-binofuranosyl cytosine in the treatment of relapsed or refrac-tory acute leukaemia. Cancer Res 1989; 49: 477-81. (P2/51)
   Google Scholar
• Daghestani A, Arlin ZA, Leyland-Jones B, et al. Phase I and II cinical and pharmacological study of 4-methoxy daunoru-bicin (idarubicin) in adult patients with acute leukaemia. Cancer Res 1985; 45: 1408–15. (P2/28)
   Google Scholar
• Harrousseau JL, Hurteloup P, Reiffers J, et al. Idarubicin in the treatment of refractory acute myeloid leukaemia. Cancer Treatm Rep 1987; 71: 991-2. (P2/42)
   Google Scholar
• Berman E, Heller G, Santorsa J, et al. Results of a ran-domised trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukaemia. Blood 1991; 77: 1666-74. (C2/120)
   Google Scholar
• Mandelli F, Petti MC, Ardia A, et al. A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Cooperative Group GIMEMA. Eur J Cancer 1991; 27: 750-5. (C2/249)
   Google Scholar
• Reiffers J, Huguet F, Stoppa AM, et al. A prospective randomised trial of idarubicin vs daunorubicin in combina-tion chemotherapy for acute myelogenous leukaemia of the age group 55 to 75. Leukaemia 1996; 10: 389-95. (C2/220)
   Google Scholar
• Vogler WR, Velez-Garcia E, Weiner RS, et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukaemia: A South-eastern Cancer Study Group. J Clin Oncol 1992; 10: 1103-11. (C2/218)
   Google Scholar
• Wiernik PH, Banks PL, Case DC, Jr, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukaemia. Blood 1992; 79: 313-9. (C2/214)
   Google Scholar
• Berman E, Wiernik P, Vogler R, et al. Long-term follow-up of three randomized trials comparing idarubicin and daunorubicin as induction therapies for patients with un-treated acute myeloid leukaemia. Cancer Suppl 1997; 11: 2181-5. (C2/552)
   Google Scholar
• The AML Collaborative Group. A systemic collaborative overview of randomised trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. Br J Haematol 1998; 103: 100–9. (M1/1 897)
   Google Scholar
• Björkholm M, Bjornsdottir J, Stenke L, et al. Mitoxantrone, etoposide and cytarabine in the treatment of acute non-lymphocytic leukaemia. Med Oncol 1990; 47: 112–4. (P2/53)
   Google Scholar
• Estey EH, Keating MJ, Mc Credie KB, et al. Phase II trial of mitoxantrone in patients with acute leukaemia in relapse. Cancer Treat Rep 1983; 67: 389-96. (P3/41)
   Google Scholar
• Hiddemann W, Kreutzmann H, Straif K, et al. High dose cytosine arabinoside and mitoxantrone: A highly effective regimen in refractory acute myeloid leukaemia. Blood 1987; 69: 744-9. (P3/40)
   Google Scholar
• Arlin Z, Case DC, Jr, Moroe J, et al. Randomised multicenter trial of cytosine arabinoside with mitoxantrone or daunoru-bicin in previously untreated adult patients with acute non-lymphocytic leukaemia. Leukaemia 1990; 4: 177-83. (C2/200)
   Google Scholar
• Lowenberg B, Suciu S, Archimbaud E, et al. Mitoxantrone vs daunorubicin in induction-consolidation chemotherapy-the value of low-dose cytarabine for maintenance of remis-sion, and an assessment of prognostic factors in acute myeloid leukaemia in the elderly: final report. European Organization of the Research and Treatment of Cancer and the Dutch-Bel-gian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol 1998; 16: 872-81. (C1/489)
   Google Scholar
• Paul C, Tidefelt U, Gahrton G, et al. A randomised compari-son of doxorubicin and doxorubicin-DNA in the treatment of acute non-lymphoblastic leukaemia. Leuk Lymphoma 1991; 3: 335-64. (C2/121)
   Google Scholar
• Bjorkholm M, Gahrton G, Grimfors G, et al. Mitoxantrone, etoposide and ara-C vs doxorubicin-DNA, ara-C, thogua-nine, vincristine and prednisolone in the treatment of patients with acute myelocytic leuekmia. A randomised comparison. Eur J Hematol 1995; 55: 19-23. (C3/86)
   Google Scholar
• Rivera G, Avery T, Roberts D. Response to L1210 to combination of cytosinarabinoside and VM-26 or VP16-213. Eur J Cancer 1975; 11: 639–47. (0)
   Google Scholar
• Bishop JF, Lowenthal RM, Joshua D, et al. Etoposide in acute nonlymphocytic leukaemia. Australian leukaemia group. Blood 1990; 75: 27-32. (C1/264)
   Google Scholar
• Hann IM, Stevens RF, Goldstone AH, et al. Randomised comparison of DAT vs ADE as induction chemotherapy in children and younger adults with acute myeloid leukaemia: results of the Medical Research Council's 10th AML trial (MRC AML 10). Blood 1997; 89: 2311–8. (C1/1 857, 1572 adults)
   PubMed Web of Science ®Google Scholar
• Carey RW, Ribas-Momdo M, Ellison RR, et al. Comparative study of cytarabinoside therapy alone and combined with thioguanine, mercaptopurin or daunorubicin in acute myelo-cytic leukaemia Cancer 1975; 36: 1560–5. (C2/326)
   Google Scholar
• Omura GA, Vogler WR, Lefante JR, et al. Treatment of acute myelogenous leukaemia: influence of three induction regi-mens. Cancer 1982; 49: 1530-6. (C2/396)
   Google Scholar
• Preisler H, David RB, Kirshner J, et al. Comparison of 3 remission induction regimens and two post-induction regi-mens for the treatment of acute non-lymphocytic leukaemia. Blood 1987; 69: 1441-9. (C2/253)
   Google Scholar
• Bishop JF. Intensified therapy for acute myeloid leukaemia. N Engl J Med 1994; 331: 941-2. (C1/264)
   Google Scholar
• Rees JK, Gray RG, Wheatley K. Dose intensification in acute myeloid leukaemia: greater effectiveness at lower cost. Princi-pal report of the Medical Research Council's AML9 study. MRC Leukaemia in Adults Working Party. Br J Haematol 1996; 94: 89–98. (C1/972)
   Google Scholar
• Castaigne S, Archimbaud E, Bordessoule D, et al. Sequential induction or double induction chemotherapy increase disease free survival compared with '3 ± 7' chemotherapy in less than 50 years adults with acute myeloid leukaemia (AML). Blood 1996;88\(Suppl 1): 291 Abstr 1153. (C3/307)
   Google Scholar
• Jehn U. Long-term outcome of post-remission chemotherapy for adults with acute myeloid leukaemia using different dose-intensities. Leuk Lymphoma 1994; 15: 99-112. (P1/122)
   Google Scholar
• Cassileth PA, Lynch E, Hines JD, et al. Varying intensity of postremission therapy in acute myeloid leukaemia. Blood 1992; 80: 1924-30. (C2/170)
   Google Scholar
• Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremis-sion chemotherapy in adults with acute myeloid leukaemia. Cancer and Leukaemia Group B. N Engl J Med 1994; 331: 896–903. (P1/1088; C1/693)
   PubMed Web of Science ®Google Scholar
• Cassileth PA, Harrington DP, Hines JD, et al. Maintenance chemotherapy prolongs remission duration in adult acute non-lymphocytic leukaemia. J Clin Oncol 1988; 6: 583-7. (C3/51)
   Google Scholar
• Fopp M, Fey MF, Bacchi M, et al. Post-remission therapy of adult acute myeloid leukaemia: one cycle of high-dose vs standard-dose cytarabine. Leukaemia Project Group of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 1997; 8: 251-7. (C2/137)
   Google Scholar
• Vogler WR, Weiner RS, Moore JO, et al. Long-term follow-up of a randomised post-induction therapy trial in acute myelogenous leukaemia. Leukaemia 1995; 9: 456-60. (C2/ 398)
   Google Scholar
• Bfichner T, Hiddeman W, Wormann H, et al. Late events in AML. Data from long-term observation of patients in two trials starting in 198 1 and 1985. Blood 1997; (Suppl 1): Abstr 2247. (C3/321)
   Google Scholar
• Prentice HG, Macdonald ID, Hamon MD. The role of immunotherapy in the treatment of acute myeloblastic leukaemia from allogeneic bone marrow transplantation to the application of IL-2. Cancer Treat Res 1993; 64: 121–34. (L)
   Google Scholar
• Hellstrand K, Mellquist UH, Wallhult E, et al. Histamine and interleukin-2 in acute myelogenous leukaemia. Leuk Lymphoma. 1997; 27: 429-38. (P 3/22)
   Google Scholar
• Thalhammer F, Geissler K, Kyrle PA, et al. Duration of second complete remission in patients with acute myeloid leukaemia treated wih chemotherapy; a retrospective single-center study. Ann Hematol 1996; 72: 216-22. (R2/168)
   Google Scholar
• Welborn JL, Lewis JP, Meyers FJ. Impact of reinduction regimens on the clinical course of adult acute non-lymphocytic leukemia. Leukemia 1988; 11: 711–6. (L)
   Google Scholar
• Plunkett W, Iacoboni S, Estey E, et al. Pharmacologically directed ara-C therapy for refractory leukaemia. Semin Oncol 1985; 2: 20–30. (L)
   Google Scholar
• Rudnick SA, Cadman EC, Capizzi RL, et al. High dose cytosine arabinoside (HIDAC) in refractory acute leukaemia. Cancer 1979; 44: 1189-93. (P3/13)
   Google Scholar
• Vogler WR, Mc Carley DL, Stagg M, et al. A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukaemia. Leukaemia 1994; 8: 1847-53. (C2/131)
   Google Scholar
• Hiddemann W, Aul C, Maschmeyer G, et al. High dose vs intermediate dose cytosine arabinoside combined with mi-toxantrone for the treatment of relapsed and refractory acute myeloid leukaemia. Leuk Lymphoma 1993; 10: 133-7. (C2/ 186)
   Google Scholar
• Archimbaud E, Thomas X, Lebland V, et al. Time sequen-tial chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial. J Clin Oncol 1995; 13: 11-8. (P1/133)
   Google Scholar
• Kantarjian HM, Keating MJ, Walters RS, et al. The charac-teristics and outcome of patients with late relapse acute myelogenous leukemia. J Clin Oncol 1988; 6: 232-8. (R3/58)
   Google Scholar
• Legha SS, Keating MJ, Mc Credie KB, et al. Evaluation of AMSA in previously treated patients with acute leukaemia. Results of therapy in 109 adults. Blood 1982; 60: 484–9. (P2/109)
   PubMed Web of Science ®Google Scholar
• Hines JD, Oken M, Mazza J, et al. High dose cytosine arabinoside (ara-C) and M-AMSA is effective therapy in relapsed acute non-lymphocytic leukaemia (ANLL). J Clin Oncol 1984; 2: 545-9. (P3/40)
   Google Scholar
• Wahlin A, Brinch L, Hornsten P, et al. Outcome of a multicenter treatment program including autologous or allo-geneic bone marrow transplantation for de novo acute leukemia. Eur J Haematol 1997; 58: 223-40. (P2/118)
   Google Scholar
• Lambertenghi-Deliliers G, Maiolo AT, Annalore C, et al. Idarubicin in sequential combination with cytosinara-binoside in the treatment of relapsed and refractory acute nonlymphoblastic leukaemia. Eur J Cancer Clin Oncol 1987; 23: 1041–5. (P2/16)
   Google Scholar
• Clavio M, Carrara P, Miglino M, et al. High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukaemia. Hematol 1996; 81: 513-20. (P2/51)
   Google Scholar
• Estey E, Plunkett W, Gandhi V, et al. Fludarabine and arabinosyl cytosine therapy of refractory and relapsed acute myelogenous leukaemia. Leuk Lymphoma 1993; 9: 343-50. (P2/59)
   Google Scholar
• Krough-Jensen M, Stentoft J. Low-dose cytosine ara-binoside in the treatment of relapsed and refractory acute non-lymphocytic leukaemia. Acta Haematol 1986; 76: 127–9. (P3/10)
   Google Scholar
• List AF, Spier C, Greer J, et al. Phase I/II trial of cy-closporine as a chemotherapy-resistance modifier in acute leukaemia. J Clin Oncol 1993; 11: 1652-60. (P2/42)
   Google Scholar
• Clift RA, Buckner CD, Thomas ED, et al. The treatment of acute non-lymphocytic leukaemia by allogeneic marrow transplantation. Bone Marrow Transplant 1987; 2: 243-58. (R1/363)
   Google Scholar
• Gorin NC, Labopin M, Fouillard L, et al. Retrospective evaluation of autologous bone marrow transplantation vs allogeneic bone marrow transplantation from an HLA iden-tical related donor in acute myelocytic leukaemia. A study of the European Cooperative Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1996; 18: 111–7. (R1/1 696; 1 114 adults transplanted in CR1, 288 in CR2)
   Google Scholar
• Gale RP, Horowitz MM, Rees JK, et al. Chemotherapy vs transplants for acute myelogenous leukaemia in second re-mission. Leukaemia 1996; 10: 13-9. (R2/501)
   Google Scholar
• Horowitz MM, Gale RP, Sondel PM, et al. Graft vs leukaemia reactions after bone marrow transplantations. Blood 1990; 75: 555-62. (0)
   Google Scholar
• Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-vs host disease in human recipients of allo-genic-marrow grafts. New Engl J Med 1979; 304: 1529-33. (0)
   Google Scholar
• Ringden O, Hermans J, Labopin M, et al. The highest leukaemia-free survival after allogeneic bone marrow trans-plantation is seen in patients with grade I acute graft-vs-host disease. Acute and Chronic Leukaemia Working Parties of the European Group for Blood and Marrow Transplanta-tion (EBMT). Leuk Lymphoma 1996; 24: 71-9. (R1/2122)
   Google Scholar
• Beatty PG, Kollman C, Howe CW. Unrelated-donor mar-row transplants: the experience of the National Marrow Donor Program. Clin Transpl 1995; 3: 271–7. (L)
   Google Scholar
• Schiller G, Feig SA, Tenho M, et al. Treatment of advanced acute leukaemia with allogeneic bone marrow transplanta-tion from unrelated donors. Br J Haematol 1994; 88: 72-8. (R3/55)
   Google Scholar
• Ringden O, Labopin M, Gluckman E, et al. Donor search or autografting in patients with acute leukaemia who lack an HLA-identical sibling? A matched-pair analysis. Acute Leukaemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation (EBMT) and the International Marrow Unrelated Search and Transplant (EVIUST) Study. Bone Marrow Transplant 1997; 19: 963–8. (R2/191 unrelated, 382 autologous)
   Google Scholar
• Jones JR, Vogelsang GB, Hess AD, et al. Induction of graft vs host disease after autologous bone marrow transplanta-tion. Lancet 1989; 1: 754-7. (0)
   Google Scholar
• Talbot DC, Powles RL, Sloane JP, et al. Cyclosporin in-duced graft vs host disease after autologous bone marrow transplantation for acute myeloid leukaemia. Bone Marrow Transplant 1990; 6: 17-20. (P3/9)
   Google Scholar
• Burnett AK, Tansey P, Watkins S, et al. Transplantation of unpurged autologous marrow for acute myeloid leukaemia in first remission. Lancet 1984; 2: 1068-70. (P3/12)
   Google Scholar
• Burnett AK, Goldstone AH, Stevens RMF, et al. Ran-domised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy results of MRC AML 10 trial for acute myeloid leukaemia in first remission. The Lancet 1998; 351: 700-8. (C1/381)
   Google Scholar
• Imrie K, Dicke KA, Keating A. Autologous bone marrow transplantation for acute myeloid leukaemia. Stem Cells 1996; 14: 69-78. (0)
   Google Scholar
• Gorin NC, Labopin MM, Meloni G, et al. Autologous bone marrow transplantation for acute myeloblastic leukaemia in Europe: further evidence of the role of marrow purging by mafosfamide. Leukaemia 1991; 5: 896–904. (R1/773 adults, 263 autotransplanted)
   PubMed Web of Science ®Google Scholar
• Mehta J, Powels R, Singhal S, et al. Autologous bone marrow transplantation for acute myeloid leukaemia in first remission: identification of modifiable prognostic factors. Bone Marrow Transplant 1995; 16: 499-506. (R2/74)
   Google Scholar
• Gorin NC, Labopin M. On behalf of the ALWP. Analysis of the acute leukaemia EBMT registry. Bone Marrow Trans-plant 1997; 19: Abstr 307. (R3/3 850 allo ± 3 366 auto)
   Google Scholar
• Ljungman P, de Witte T, Verdonck L, et al. Bone marrow transplantation for acute myeloblastic leukaemia: an EBMT Leukaemia Working Party prospective analysis from HLA-typing. Br J Haematol 1993; 84: 61-6. (P2/147)
   Google Scholar
• Archimbaud E, Thomas X, Michallet M, et al. Prospective genetically randomised comparison between intensive post-induction therapy and bone marrow transplantation in adults with newly diagnosed acute myeloid leukaemia. J Clin Oncol 1994; 12: 262-7. (C3/78)
   Google Scholar
• Beatty PG. Bone marrow transplantation for the treatment of hematologic diseases: status in 1994. Exp Hematol 1995; 23: 277–88. (L)
   PubMedGoogle Scholar
• Appelbaum FR. Allogeneic haematopoetic transplantation for acute leukaemia. Sem Oncol 1997; 24: 114–23. (L)
   PubMedGoogle Scholar
• Reiffers J, Stoppa AM, Hugues F, et al. The role of allo-geneic transplantation in the younger adults with acute myeloid leukaemia in first remission: a ten year experience. Blood 1996; 88 (Suppl 1): Abstr 2721. (P3/286)
   Google Scholar
• Reiffers J, Stoppa AM, Attal M, et al. Allogeneic vs au-tologous stem cell transplantation vs chemotherapy in pa-tients with acute myeloid leukaemia in first remission. The BMGT'87 study. Leukaemia 1996; 10: 1874–82. (P2/204, 162 CR; C3/77)
   PubMed Web of Science ®Google Scholar
• Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogenic bone marrow transplantation in the management of acute myeloid leukaemia in first remission. New Engl J Med 1998; 339: 1649–64. (P1/740, induction therapy; 346 in CR, of whom 113 had an allogeneic transplant and C2/233, post-remission therapy)
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Cahn J, Pignon B, et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukaemia. The Groupe Ouest Est Leucémies Aigu8s Myéloblastiques (GOELAM). Blood 1997; 90: 2978–86. (P1/ 517; 367 in CR; C2/164)
   Google Scholar
• Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with in-tensive chemotherapy in acute myelogenous leukaemia. N Engl J Med 1995; 332: 217–23. (P1/990; 422 CR; 168 allogeneic transplantation; C2/254 autologous transplanta-tion or chemotherapy)
   PubMed Web of Science ®Google Scholar
• Keating S, de Witte T, Sucio S, et al. The influence of HLA-matched sibling donor availability on treatment out-come for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA. Br J Haematol 1998; 339: 1344-53. (C2/831)
   Google Scholar
• Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-vs-leukaemia effect of donor lymphocyte transfusions in mar-row grafted patients. EBMT Chronic Leukaemia Working Parties. Blood 1995; 5: 2041–50. (P2/135, 23 AML)
   Google Scholar
• Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-vs-leukaemia without myeloablative therapy. Blood 1997; 12: 4531-6. (P3/15)
   Google Scholar
• Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cy-toreduction for the treatment of malignant and nonmalig-nant hematologic diseases. Blood 1998; 91: 756-63. (P3/26)
   Google Scholar
• Keating MJ, Katarjian H, Smith TL, et al. Response to salvage therapy and survival after relapse in acute myeloge-nous leukemia. J Clin Oncol 1989; 7: 1071-80. (R2/243)
   Google Scholar
• Petersen FB, Lynch MH, Clift R, et al. Autologous marrow transplantation for patients with acute myeloid leukemia in untreated first relapse or in second compete remission. J Clin Oncol 1993; 11: 1353-60. (R3/47)
   Google Scholar
• Chopra R, Goldstone AH, McMillan AK, et al. Successful treatment of acute myeloid leukemia beyond first remission with autologous bone marrow transplantation using busul-fan/cyclophosphamide and unpurged marrow. The British Autograft Group experience. J Clin Oncol 1991; 9: 1840-7. (R3/34)
   Google Scholar
• Biggs JC, Horowitz MM, Gale RP, et al. Bone marrow transplants may cure patients with acute leukaemia never achieving remission with chemotherapy. Blood 1992; 80: 1090-3. (P2/88)
   Google Scholar
• Forman SJ, Scmidt GM, Nademanee AP, et al. Allogeneic bone marrow transplantation as therapy for primary induc-tion failure for patients with acute leukaemia. J Clin Oncol 1991; 9: 1570-4. (R3/21)
   Google Scholar
• Cartwright RA, Staines A. Acute leukaemias. In: Fleming A T, ed. Epidemiology of hematological disease. Part 1, vol. 5. Bailliere's Clin Hematol, 1992: 1–26. (L)
   Google Scholar
• Taylor PR, Reid MM, Stark AN, et al. De novo acute myeloid leukaemia in patients over 55-years-old: a popula-tion based study of incidence, treatment and outcome. Northern Region Haematology Group. Leukaemia 1995; 9: 231-7. (P2/200)
   Google Scholar
• Johnson PR, Hunt LP, Liu Yin JA. Prognostic factors in elderly patients with acute myeloid leukaemia: development of a model to predict survival. Br J Haematol 1993; 85: 300-6. (P2/104)
   Google Scholar
• Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukaemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemother-apy. Blood 1997; 89: 3323-39. (C2/211)
   Google Scholar
• Hamblin T. The treatment of acute myeloid leukaemia pre-ceded by the myelodysplastic syndrome. Leukaemia Res 1992; 16: 101–8. (L)
   PubMed Web of Science ®Google Scholar
• Hast R, Wide S. Dysplastic peripheral blood polymorphs link acute myeloblastic leukaemia in elderly to myeloblastic syndromes. Eur J Haematol 1992; 48: 163-7. (0)
   Google Scholar
• Nussler V, Saver H, Pelka-Fleischerf R, et al. Clinical bio-chemical and cytokinetic parameters for distinguishing smouldering and rapidly proliferating variants of acute leukaemia. Eur J Hematol 1990; 45: 19-25. (0)
   Google Scholar
• Howe RB, Bloomfield CD, Mc Kennan, et al. Hypocellular acute leukaemia, Am J Med 1982; 72: 391–5. (0)
   Google Scholar
• Rees JK, Gray RG, Swirsky D, etal. Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial. Lancet 1986; 2: 1236-41. (C1/1127)
   Google Scholar
• Bfichner T, Urbanitz D, Hiddemann W, et al. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukaemia (AML): two multicenter studies of the German AML Cooperative Group. J Clin Oncol 1985; 3: 1583-9. (C2/143)
   Google Scholar
• Lowenberg B, Zittoun R, Kerkhofs H, etal. On the value of intensive remission induction chemotherapy in elderly pa-tients of 65 ± years with acute myeloid leukaemia: a ran-domised phase III study of the European Organisation for Research and Treatment of Cancer Leukaemia Group. J Clin Oncol 1989; 7: 1268-74. (C2/71)
   Google Scholar
• Detourmignies L, Wattel E, Lai JL, et al. Is there still a role for low-dose cytosine arabinoside in de novo acute myeloid leukaemia in the elderly? Ann Hematol 1993; 66: 235-40. (P2/77)
   Google Scholar
• Powell B, Capizzi R, Muss HB, et al. Low-dose ara-C therapy for acute myelogenous leukaemia in elderly patients. Leukaemia 1989; 3: 23-8. (P2/44)
   Google Scholar
• Tilly H, Castaigne S, Bordessoule D, et al. Low dose cytara-bine vs intensive chemotherapy in the treatment of acute non-lymphocytic leukaemia in the elderly. J Clin Oncol 1990; 8: 272–9. (C2/126; 87 randomised)
   PubMed Web of Science ®Google Scholar
• Baudard M, Marie JP, Cadiou M, et al. Acute myeloid leukaemia in the elderly: retrospective study of 235 consecu-tive patients. Brit J Haematol 1994; 86: 82-91. (R1/235)
   Google Scholar
• Foon KA, Zighelboim J, Yale C, et al. Intensive chemother-apy is the treatment of choice for elderly patients with acute myelogenous leukaemia. Blood 1981; 3: 467-70. (R2/107)
   Google Scholar
• Ruutu T, Almqvist A, Hallman H, et al. Oral induction and consolidation of acute myeloid leukaemia with etoposide, 6-thiogunine, and idarubicin (ETI) in elderly patients: a randomised comparison with 5-day TAD. Leukaemia 1994; 8: 11-5. (C3/51)
   Google Scholar
• Bfichner T, Hiddeman W, Worman B, et al. Daunorubicin 60 instead of 30 mg/m2 improves response and survival in elderly patients with AML. Blood 1997; 583 (Suppl 1): Abstr 504. (C3/340)
   Google Scholar
• Feldman EJ, Seiter K, Damon L, et al. A randomised trial of high-vs standard dose mitoxantrone with cytarabine in elderly patients with acut myeloid leukaemia. Leukaemia 1997; 11: 485-9. (C3/54)
   Google Scholar
• Bow EJ, Sutherland JA, Kilpatrick MG, et al. Therapy of untreated acute myeloid leukaemia in the elderly: remission induction using a non-cytarabine-containing regimen of mi-toxantrone plus etoposide. J Clin Oncol 1996; 14: 1345-52. (P2/67)
   Google Scholar
• Pascarella A, Marrani C, Leoni F, et al. Low-dose cy-tosinearabinoside in patients with acute myeloid leukaemia not eligible for standard chemotherapy. Leuk Lymphoma 1995; 18: 465-9. (R2/131)
   Google Scholar
• Bassan R, Buelli M, Viero P, etal. The management of acute myelogenous leukaemia in the elderly: Ten year experience in 118 patients. Hematol Oncol 1992; 10: 25-60. (R2/118)
   Google Scholar
• Liu Yin JA, Johnson PR, Davies JM, et al. Mitoxantrone and cytosine arabinoside as first-line therapy in elderly pa-tients with acute myeloid leukaemia. Br J Haematol 1991; 79: 415–20. (P2/104; 86 de novo)
   PubMed Web of Science ®Google Scholar
• Montastruc M, Reiffers J, Stoppa AM, et al. Treatment of acute myeloid leukaemia in elderly patients: the influence of maintenance therapy (BGM 84 protocol). Nouv Rev Franc d'Hematol 1990; 32: 147–52. (P2/92; C3/47)
   PubMedGoogle Scholar
• Rowe JM, Andersen JP, Mazza JJ, et al. A randomised placebo-controlled phase III study of granulocyte-macrophage colonystimulating factor in adult patients (55 to 70 years of age) with acute myelogenous leukaemia (AML): a study of the Eastern Cooperative Oncology Group (E1490). Blood 1995; 86: 457-62. (C2/117)
   Google Scholar
• Lowenberg B, Suciu S, Archimbaud E, et al. Use of recom-binant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukaemia: final report of AML-11, a phase III randomised study of the Leukaemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Coopera-tive Group. Blood 1997; 8: 2952-61. (C1/318)
   Google Scholar
• Stone RM, George SL, Berg DT. Granulocyte macrophage colony stimulating factor after initial chemotherapy for el-derly patients with primary acute myelogenous leukaemia. N Engl J Med 1995; 332: 1671–7. (C1/388; 347 randomised)
   Google Scholar
• Heil G, Hoelzer D, Sanz MA, et al. A randomised, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukaemia. The International Acute Myeloid Leukaemia Study Group. Blood 1997; 90: 4710-8. (C1/521)
   Google Scholar